Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | 2CO3.Ca.Mg |
| Molecular Weight | 184.401 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Mg++].[Ca++].[O-]C([O-])=O.[O-]C([O-])=O
InChI
InChIKey=HHSPVTKDOHQBKF-UHFFFAOYSA-J
InChI=1S/2CH2O3.Ca.Mg/c2*2-1(3)4;;/h2*(H2,2,3,4);;/q;;2*+2/p-4
| Molecular Formula | CO3 |
| Molecular Weight | 60.0089 |
| Charge | -2 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | Ca |
| Molecular Weight | 40.078 |
| Charge | 2 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | Mg |
| Molecular Weight | 24.305 |
| Charge | 2 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/mesh/67028042Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/8342726 | https://www.ncbi.nlm.nih.gov/pubmed/3415787 | https://www.ncbi.nlm.nih.gov/pubmed/23115717
Sources: https://www.ncbi.nlm.nih.gov/mesh/67028042
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/8342726 | https://www.ncbi.nlm.nih.gov/pubmed/3415787 | https://www.ncbi.nlm.nih.gov/pubmed/23115717
Calcium magnesium carbonate (dolomite), a mineral with the chemical formula CaMg(CO3)2, is made up of 60% calcium carbonate (equivalent to 24% calcium) and 40% magnesium carbonate (equivalent to 12% magnesium). It is recommended by lay periodicals as a desirable source of calcium and magnesium, but found to be also a source of potentially toxic heavy metals. Exposure to high atmospheric concentrations of this compound is likely to be associated with respiratory symptoms.
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23115717
Curator's Comment: Deodat Gratet de Dolomieu, a French geologist, was the first to describe dolomite in 1791.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Comparative cytotoxicity of dolomite nanoparticles in human larynx HEp2 and liver HepG2 cells. | 2015-06 |
|
| Evaluation of cytotoxic, oxidative stress, proinflammatory and genotoxic responses of micro- and nano-particles of dolomite on human lung epithelial cells A(549). | 2012-09 |
|
| Nanotoxicity of dolomite mineral of commercial importance in India. | 2011-02 |
|
| Effect of dolomite on the repair of bone defects in rats: histological study. | 2010-12 |
|
| Antiviral activities of heated dolomite powder. | 2008-12 |
|
| Effects of calcium magnesium carbonate and roughage level on feedlot performance, ruminal metabolism, and site and extent of digestion in steers fed high-grain diets. | 2008-11 |
|
| Effect of dolomite oral exposure in Wistar rats during organogenesis period of pregnancy. | 2008-09 |
|
| Dolomite supplementation improves bone metabolism through modulation of calcium-regulating hormone secretion in ovariectomized rats. | 2005 |
|
| Antitumoral effect of bleomycin+dolomite combination treatment, in mice bearing Ehrlich ascites carcinoma. | 1993-09-01 |
|
| Alert to users of calcium supplements as antihypertensive agents due to trace metal contaminants. | 1988-07 |
Patents
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22785077
Dolomite powder contained particles of different shapes and size both microparticles (MPs) and nanoparticles (NPs), suggesting potential occupational exposure of these particles. An attempt was therefore, made to investigate dolomite toxicity in a particle size-dependent manner in human lung epithelial cells A(549). cytotoxicity profiles were estimated by exposing cells at concentration doses 100–1000 ug/ml by two different methods. LC50 values of MPs were 655 ug/ml and 675 ug/ml whereas for NPs were 278 ug/ml and 300 ug/ml in MTT and Trypan blue assays, respectively.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 20:20:07 GMT 2025
by
admin
on
Mon Mar 31 20:20:07 GMT 2025
|
| Record UNII |
UG9H2002BF
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Systematic Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
DSLD |
1574 (Number of products:2)
Created by
admin on Mon Mar 31 20:20:07 GMT 2025 , Edited by admin on Mon Mar 31 20:20:07 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID70892191
Created by
admin on Mon Mar 31 20:20:07 GMT 2025 , Edited by admin on Mon Mar 31 20:20:07 GMT 2025
|
PRIMARY | |||
|
7000-29-5
Created by
admin on Mon Mar 31 20:20:07 GMT 2025 , Edited by admin on Mon Mar 31 20:20:07 GMT 2025
|
PRIMARY | |||
|
61833
Created by
admin on Mon Mar 31 20:20:07 GMT 2025 , Edited by admin on Mon Mar 31 20:20:07 GMT 2025
|
PRIMARY | |||
|
230-274-9
Created by
admin on Mon Mar 31 20:20:07 GMT 2025 , Edited by admin on Mon Mar 31 20:20:07 GMT 2025
|
PRIMARY | |||
|
SUB33635
Created by
admin on Mon Mar 31 20:20:07 GMT 2025 , Edited by admin on Mon Mar 31 20:20:07 GMT 2025
|
PRIMARY | |||
|
696
Created by
admin on Mon Mar 31 20:20:07 GMT 2025 , Edited by admin on Mon Mar 31 20:20:07 GMT 2025
|
PRIMARY | |||
|
UG9H2002BF
Created by
admin on Mon Mar 31 20:20:07 GMT 2025 , Edited by admin on Mon Mar 31 20:20:07 GMT 2025
|
PRIMARY | |||
|
C028042
Created by
admin on Mon Mar 31 20:20:07 GMT 2025 , Edited by admin on Mon Mar 31 20:20:07 GMT 2025
|
PRIMARY | |||
|
806
Created by
admin on Mon Mar 31 20:20:07 GMT 2025 , Edited by admin on Mon Mar 31 20:20:07 GMT 2025
|
PRIMARY | |||
|
100000127590
Created by
admin on Mon Mar 31 20:20:07 GMT 2025 , Edited by admin on Mon Mar 31 20:20:07 GMT 2025
|
PRIMARY | |||
|
240-440-2
Created by
admin on Mon Mar 31 20:20:07 GMT 2025 , Edited by admin on Mon Mar 31 20:20:07 GMT 2025
|
ALTERNATIVE | |||
|
23622
Created by
admin on Mon Mar 31 20:20:07 GMT 2025 , Edited by admin on Mon Mar 31 20:20:07 GMT 2025
|
PRIMARY | RxNorm | ||
|
16389-88-1
Created by
admin on Mon Mar 31 20:20:07 GMT 2025 , Edited by admin on Mon Mar 31 20:20:07 GMT 2025
|
ALTERNATIVE |